Medicenna Therapeutics discloses Form D for private securities offering

Medicenna Therapeutics Corp. filed a Form D with the Securities and Exchange Commission disclosing a private securities offering. The company was previously known as A2 Acquisition Corp.¹ It is incorporated in Canada at the federal level and has existed for over five years.¹

The filing lists the company's principal place of business as 2 Bloor Street W, Suite 903, Toronto, Ontario, Canada.¹

The offering involves units. Each unit is comprised of 1 common share and 1/2 of 1 common share purchase warrant, with each warrant entitling the holder to purchase one additional share at an exercise price of CDN$0.65 per share for a period of 3 years following May 28, 2026.¹

According to the filing, the date of first sale was May 28, 2026, and this is a new notice filing rather than an amendment.¹

On the financial terms, the total offering amount is $2,343,400 USD, with $253,458 USD already sold and $2,089,942 USD remaining to be sold.¹ The filing clarified that the additional $2,089,942 may be received upon the exercise of common share purchase warrants if exercised in the U.S., with U.S. dollar amounts based on the Bank of Canada average rate of exchange reported on May 28, 2026, which was CDN$1.3809 = US$1.00.¹

Regarding investor participation, the total number of investors who had already invested in the offering was 3.¹

The filing indicated no sales commissions were paid. Sales commissions and finders' fees were both listed as $0 USD.¹

On use of proceeds, the amount designated for payments to executive officers, directors or promoters was $0 USD, though the filing noted that in the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.¹

The notice was signed by David Hyman, Chief Financial Officer of Medicenna Therapeutics Corp., dated 2026-07-06.¹